Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

Funding Opportunity PAR-23-131 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding